#166
|
|||
|
|||
×òîáû ãîâîðèòü î êîêðåòíîé ñòèìóëÿöèè, íàäî âèäåòü ÿè÷íèêè è ïàöèåíòêó. Äåéëè è äåïî ôîðìû - ñîâåðøåííî ðàçëè÷íû ïî ñèëå ñâîåãî äåéñòâèÿ.
__________________
Àíøèíà Ìàðãàðèòà Áåíèàìèíîâíà, äèðåêòîð êëèíèêè ÔåðòèÌåä, ã. Ìîñêâà. Âèöå-ïðåçèäåíò Ðîññèéñêîé Àññîöèàöèè Ðåïðîäóêöèè ×åëîâåêà, ×ëåí ñîâåòà ESHRE. Çàïèñü íà êîíñóëüòàöèþ: (495) 504-15-26, (499) 165-70-77 Äèàãíîñòèêà è ëå÷åíèå âñåõ âèäîâ áåñïëîäèÿ ìåòîäàìè ÝÊÎ, ÈÊÑÈ è äð. Ãåíåòè÷åñêàÿ äèàãíîñòèêà è ïðîôèëàêòèêà íàñëåäñòâåííûõ çàáîëåâàíèé. Äîíîðñêèå ïðîãðàììû. Ñóððîãàòíîå ìàòåðèíñòâî. Áàíê ïîëîâûõ êëåòîê. Âåäåíèå ïàöèåíòîâ îò íà÷àëà ëå÷åíèÿ áåñïëîäèÿ äî ðîäîâ. |
#167
|
|||
|
|||
Äîáðûé äåíü, Ìàðãàðèòà Áåíèàìèíîâíà!
Ïðîêîíñóëüòèðóéòå, ïîæàëóéñòà, ÈÈ áåç ñòèìóëÿöèè ãîíàòðîïèíàìè, íî ñ ïðèìåíåíèåì ýñòðîãåíîâ (ïðîãèíîâà) è óòðîæåñòàíà îòíîñÿòñÿ ê ÈÈ â åñòåñòâåííîì öèêëå èëè íåò? ×èòàëà, ÷òî ÈÈ â ïðèíöèïå ïðîâîäÿò 1-2 ðàçà çà íåñêîëüêî äíåé äî îâóëÿöèè (à òàêæå â äåíü îâóëÿöèè èíîãäà), èòîãî 2-3 ðàçà. 1. Åñëè ýíäîìåòðèé áóäåò îòñòàâàòü â ðàçìåðàõ, òî íàçíà÷àþò ëè òîãäà ýñòðîãåíû (ïðîãèíîâó) äëÿ íàðàùèâàíèÿ ýíäîìåòðèÿ? 2. Íàäî ëè äî ïðîâåäåíèÿ ÈÈ â ÅÖ çàìåðèòü óðîâåíü ïðîãåñòåðîíà â êðîâè, ÷òîá áûòü óâåðåííûìè, ÷òî óòðîæåñòàí íå íóæåí? Ïðîñòî "íà âñÿêèé ñëó÷àé" íå õî÷ó åãî ïðèíèìàòü. 3. È åùå, ó÷èòûâàÿ ìîé îïûò, êîãäà â ÅÖ îâóëÿöèÿ ïðîèçîøëà ñëèøêîì áûñòðî, ÷åì ïðîãíîçèðîâàëè ïðè ôîëëèêóëîìåòðèè, íå áóäåò ëè ëó÷øå ïîäñòðàõîâàòüñÿ ïðåãíèëîì? Âåäü íàäî ñèíõðîíèçèðîâàòü äåéñòâèÿ è âðåìÿ âðà÷à, ëàáîðàíòîâ, ìóæà è ìåíÿ. 4. Ñêîëüêî ðàç ïîäðÿä ìîæíî ïðîâîäèòü òàêèõ ïîïûòîê ÈÈ (ñ ïðèìåíåíèåì ïåðå÷èñëåííûõ ëåêàðñòâ) ? 5. ×åðåç ñêîëüêî öèêëîâ ìîæíî íà÷èíàòü ÝÊÎ ïîñëå ïîñëåäíåé ïîïûòêè ïîäîáíîãî ÈÈ íà ôîíå òàêîãî "íåïîëíîãî" ÇÃÒ, åñëè ïàöèåíêó íè÷åãî íå áîññïîêîèò? Î÷åíü óæ ïîõîæà âòîðàÿ ïîëîâèíà öèêëà íà ñõåìó ÇÃÒ ïðè ÝÊÎ Áîëüøîå ñïàñèáî Âàì |
#168
|
|||||||
|
|||||||
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
__________________
Àíøèíà Ìàðãàðèòà Áåíèàìèíîâíà, äèðåêòîð êëèíèêè ÔåðòèÌåä, ã. Ìîñêâà. Âèöå-ïðåçèäåíò Ðîññèéñêîé Àññîöèàöèè Ðåïðîäóêöèè ×åëîâåêà, ×ëåí ñîâåòà ESHRE. Çàïèñü íà êîíñóëüòàöèþ: (495) 504-15-26, (499) 165-70-77 Äèàãíîñòèêà è ëå÷åíèå âñåõ âèäîâ áåñïëîäèÿ ìåòîäàìè ÝÊÎ, ÈÊÑÈ è äð. Ãåíåòè÷åñêàÿ äèàãíîñòèêà è ïðîôèëàêòèêà íàñëåäñòâåííûõ çàáîëåâàíèé. Äîíîðñêèå ïðîãðàììû. Ñóððîãàòíîå ìàòåðèíñòâî. Áàíê ïîëîâûõ êëåòîê. Âåäåíèå ïàöèåíòîâ îò íà÷àëà ëå÷åíèÿ áåñïëîäèÿ äî ðîäîâ. |
#169
|
|||
|
|||
Cïàñèáî, Ìàðãàðèòà Áåíèàìèíîâíà!
Îòâåòüòå, ïîæàëóéñòà, íà âîïðîñ: ïðè ïðîâåäåíèè ÈÈ â ÅÖ, íà êàêîì äíå öèêëà (ñàìîå ïîçäíåå) íàçíà÷àþò ãîíàòðîïèíû, åñëè âèäÿò ÷òî ñâîè ôîëëèêóëû íå ðàñòóò èëè îòñòàþò â ðàçâèòèè? Ïîíÿòíî, ÷òî òîãäà ýòî áóäåò ÈÈ ñî ñòèìóëÿöèåé... Áëàãîäàðþ çà îòâåò! |
#170
|
|||
|
|||
Ýòî î÷åíü èíäèâèäóàëüíî. Ëè÷íî ÿ íå âèæó â ýòîì ñìûñëà.
__________________
Àíøèíà Ìàðãàðèòà Áåíèàìèíîâíà, äèðåêòîð êëèíèêè ÔåðòèÌåä, ã. Ìîñêâà. Âèöå-ïðåçèäåíò Ðîññèéñêîé Àññîöèàöèè Ðåïðîäóêöèè ×åëîâåêà, ×ëåí ñîâåòà ESHRE. Çàïèñü íà êîíñóëüòàöèþ: (495) 504-15-26, (499) 165-70-77 Äèàãíîñòèêà è ëå÷åíèå âñåõ âèäîâ áåñïëîäèÿ ìåòîäàìè ÝÊÎ, ÈÊÑÈ è äð. Ãåíåòè÷åñêàÿ äèàãíîñòèêà è ïðîôèëàêòèêà íàñëåäñòâåííûõ çàáîëåâàíèé. Äîíîðñêèå ïðîãðàììû. Ñóððîãàòíîå ìàòåðèíñòâî. Áàíê ïîëîâûõ êëåòîê. Âåäåíèå ïàöèåíòîâ îò íà÷àëà ëå÷åíèÿ áåñïëîäèÿ äî ðîäîâ. |
#171
|
|||
|
|||
Öèòàòà:
È ìîæíî ëè ñïåöèàëüíî òàê íàçíà÷èòü äîçû ãîíàòðîïèíîâ, ÷òîáû áûë òîëüêî îäèí äîìèíàíòíûé ôîëëèêóë â äàííîì öèêëå? |
#172
|
|||
|
|||
Óâàæàåìàÿ, Ìàðãàðèòà Áåíèàìèíîâíà!
ß óæå äàâíî îáñóæäàþ ñ Âàìè òàêóþ àëüòåðíàòèâó ÝÊÎ, êàê ÈÈ. Óæå íàñòðîèëàñü ïðîâåñòè 3 ïðîöåäóðû è åñëè âðà÷ áóäåò íàñòàèâàòü, ïðîâåðêó òðóá òîæå. ÍÎ íàòêíóëàñü íà Âàøåì ôîðóìå íà óæàñàþùóþ èíôîðìàöèþ: http://forums.rusmedserv.com/archive/index.php/t-4200 Öèòèðóþ âðà÷åé: " Ê ñîæàëåíèþ, îñëîæíåíèÿ ïîñëå èíñåìèíàöèè áûâàþò íåîáðàòèìûìè. Ñîâåòóþ - ïåðåä ïðîöåäóðîé (åñëè Âû íà íå¸ ïîéäåòå) çàðó÷èòüñÿ äîãîâîðîì î âîçìîæíîì ñòðàõîâàíèè íåîáðàòèìûõ ïîñëåäñòâèé. Ïî êàíîíàì ãèíåêîëîãèè ( à èõ íèêòî íå îòìåíÿë) âíóòðèìàòî÷íàÿ èíñåìèíàöèÿ ïðîâîäèòñÿ òîëüêî â òîì ñëó÷àå, åñëè åñòü áåñïëîäèå(äîêàçàííîå!!!!!!!), ñâÿçàííîå ñ íåñîâìåñòèìîñòüþ ñïåðìû ìóæà è øåå÷íîé ñëèçè æåíû ïðè îòñóòñòâèè äðóãèõ ïðè÷èí.Âñòðå÷àåòñÿ êðàéíå ðåäêî!" "Ê ñîæàëåíèþ, ñòàëêèâàëñÿ ñ îñëîæíåíèÿìè äàííîé ïðîöåäóðû.  íàøåì îòäåëåíèè îíà íå ïðàêòèêóåòñÿ, íî â îäíîì èç ëå÷åáíûõ ó÷ðåæäåíèé ãîðîäà äåëàþò. Ýôôåêòèâíîñòü íå çíàþ - íå ãîâîðÿò. Íî ðàçà 3-4 íà ìîåé ïàìÿòè ïðèõîäèëîñü ëå÷èòü. Êàê ïðàâèëî ïðîöåäóðà îñëîæíÿëàñü ïîÿâëåíèåì òóáîîâàðèàëüíûõ îáðàçîâàíèé. Ïàðó ðàç ýòî ïðèâåëî ê óäàëåíèþ òðóá" "Äà, ëàïàðîñêîïèè ïîòåíöèàëüíî îïàñíû ïî âîçìîæíîñòè èíäóöèðîâàòü ñïàéêîáðàçîâàíèå, îäíàêî è ÃÑà òàêæå èìååò ðèñê ðàçâèòèÿ ðÿäà îñëîæíåíèé, â òîì ÷èñëå ïðèâîäÿùèõ ê îêêëþçèè ìàòî÷íûõ òðóá. Íî èç äâóõ çîë âûáèðàþò ìåíüøåå. Êñòàòè èíîãäà ÃÑà áîëåå èíôîðìàòèâíà ÷åì äèàãíîñòè÷åñêàÿ ëàïàðîñêîïèÿ, è ìîæåò ïðîâîäèòüñÿ ïîñëå íå¸.  ÷àñòíîñòè åñëè ðå÷ü èä¸ò îá àäåíîìèîçå è ãðàíóë¸çíûõ ñàëüïèíãèòàõ. Êñòàòè ÃÑà òàêæå îòíîñèòñÿ ê èíòåðâåíòíûì ìåòîäèêàì, îñîáåííî, åñëè ýòî ñåëåêòèâíàÿ ñàëüïèíãîãðàôèÿ" ×òî ýòî çà îáðàçîâàíèÿ â òðóáàõ, êîòîðûå ÿ âûäåëèëà æèðíûì øðèôòîì? ×åñòíî, ÿ óæå íå çíàþ, ÷òî ïðåäïðèíÿòü, ÷òîáû áûñòðåå íàñòóïèëà áåðåìåííîñòü. Ïîêà òîëüêî 9é ìåñÿö ñàìîñòîÿòåëüíîãî ïëàíèðîâàíèÿ ñ âû÷åòîì âñåõ ÝÊÎ è äèàãíîñòè÷åñêèõ ïðîöåäóð, ò.î. áåñïëîäèå íå äîêàçàíî. Ïîñëå òàêèõ çàÿâëåíèé (âûøå) ÿ óæå äóìàþ ÝÊÎ ýòî ñàìîå áåçîáèäíîå. Ïðîêîìåíòèðóéòå , ïîæàëóéñòà, ýòè âûñêàçûâàíèÿ. Ýòî ïîìîæåò òàêèì êàê ÿ îáúêòèâíî âçâåñèòü âñå çà è ïðîòèâ, à íàñ î÷åíü ìíîãî... Áîëüøîå ñïàñèáî Âàì! |
#173
|
|||
|
|||
Öèòàòà:
Öèòàòà:
Öèòàòà:
__________________
Àíøèíà Ìàðãàðèòà Áåíèàìèíîâíà, äèðåêòîð êëèíèêè ÔåðòèÌåä, ã. Ìîñêâà. Âèöå-ïðåçèäåíò Ðîññèéñêîé Àññîöèàöèè Ðåïðîäóêöèè ×åëîâåêà, ×ëåí ñîâåòà ESHRE. Çàïèñü íà êîíñóëüòàöèþ: (495) 504-15-26, (499) 165-70-77 Äèàãíîñòèêà è ëå÷åíèå âñåõ âèäîâ áåñïëîäèÿ ìåòîäàìè ÝÊÎ, ÈÊÑÈ è äð. Ãåíåòè÷åñêàÿ äèàãíîñòèêà è ïðîôèëàêòèêà íàñëåäñòâåííûõ çàáîëåâàíèé. Äîíîðñêèå ïðîãðàììû. Ñóððîãàòíîå ìàòåðèíñòâî. Áàíê ïîëîâûõ êëåòîê. Âåäåíèå ïàöèåíòîâ îò íà÷àëà ëå÷åíèÿ áåñïëîäèÿ äî ðîäîâ. |
#174
|
|||
|
|||
Äîáðûé äåíü, Ìàðãàðèòà Áåíèàìèíîâíà!
Ó ìåíÿ ê Âàì íåñêîëüêî âîïðîñîâ îòíîñèòåëüíî ÈÈ, êàê ê èñòèíå â ïîñëåäíåé èíñòàíöèè : 1. Òàêèå îñëîæíåíèÿ êàê îêêëþçèè ìàòî÷íûõ òðóá è òóáîîâàðèàëüíûå îáðàçîâàíèÿ, óïîìÿíóòûå âûøå, ìîãóò âîçíèêíóòü èç-çà íàëè÷èÿ èíôåêöèé â ìàòêå èëè ñïåðìå ìóæà, èìåííî ïðè èõ åäèíîêðàòíîì ïîïàäàíèè â òðóáû â ïðîöåññå ÈÈ? Ìîæíî ëè ïåðåñòðàõîâàòüñÿ, åñëè ïðîñòî ñäåëàòü ìàçîê íà ôëîðó? õëàìèäèè, óðåà-çìó, ìèêî-çìó ïðîâåðÿþ ðåãóëÿðíî – îòñóòñòâóþò, íî ìóæà íå ïðîâåðÿëè. Èëè òîëüêî â ñëó÷àå íàëè÷èÿ ñïàåê äî ÃÑà è ÈÈ? Ïîíÿòíî, ÷òî äî ÃÑà ìîæíî òîëüêî äîãàäûâàòüñÿ îá èõ íàëè÷èè è çàñòðàõîâàòüñÿ îò òàêèõ îñëîæíåíèé íåëüçÿ... 2. Åñëè ÿ ñîáåðóñü íà ÈÈ, òî ìíå íóæíî â ñðî÷íîì ïîðÿäêå ïðîâåðèòü ìàòî÷íûå òðóáû äëÿ «äîïóñêà» ê ÈÈ. ß èùó ñàìûé ùàäÿùèé ìåòîä, ïóñòü è ìàëîèíôîðìàòèâíûé. Ñóùåñòâóþò ëè îñëîæíåíèÿ ïîñëå êèìîïåðòóáàöèè è ïíåâìîïåðòóáàöèè? Ïðàâèëüíî ëè ãîâîðÿò, êîãäà óòâåðæäàþò, ÷òî îíè áåçîïàñíû ïî ñðàâíåíèþ ñ ðåíãåíîì òðóá (ÃÑÃ)? Íàäî ëè ïîñëå íèõ ïðèíèìàòü àíèòèáèîòèêè? Çàïðåùàåòñÿ ëè áåðåìåííîñòü â öèêëå, êîãäà äåëàëè êèìîïåðòóáàöèþ è ïíåâìîïåðòóáàöèþ? ß ðåøèëà, ÷òî åñëè ïîñëå ïåðâè÷íîé ïðîâåðêè ïðîõîäèìîñòü òðóá áóäåò ïîä âîïðîñîì, òî òîãäà ïîéäó íà ëàïàðó. Òàê èëè èíà÷å, åñëè ÈÈ íå ïîìîæåò, òî êðóã çàìêíåòñÿ è ïðèäåòñÿ äåëàòü ÝÊÎ, íå îòêëàäûâàÿ. 3. Åùå õîòåëîñü áû îáñóäèòü ñ Âàìè äðóãîé ìîìåíò: îïàñàþñü, ìíå íå ïîêàçàíà ìíîãîïëîäíàÿ áåðåìåííîñòü èç-çà ïå÷åíè (íåèçâåñòíî êàê îíà îòðåàãèðóåò íà ìíîãîêðàòíîå óâåëè÷åíèå óðîâíÿ ïðîãåñòåðîíà), è ñàìîå íåìàëîâàæíîå – èç-çà íåâîçìîæíîñòè ïðîâåñòè ñêðèíèíã ïàòîëîãèé (ìíå óæå 38). Ó íàñ åñòü 2å çäîðîâûõ äåòåé, è ïîýòîìó ðèñê âûíàøèâàòü äâîéíþ íå î÷åíü ñåáÿ îïðàâäûâàåò, à âûíîñèòü îäíîãî ðåáåíêà ïðîáëåìîé îñîáîé äëÿ ìåíÿ íå áûëî. Èìååò ëè ñìûñë ïðîâîäèòü ÈÈ ñî ñòèìóëÿöèåé, åñëè çðååò òîëüêî îäèí ôîëëèêóë? Ìîæíî ëè ñïåöèàëüíî òàê íàçíà÷èòü äîçû ãîíàòðîïèíîâ, ÷òîáû áûë òîëüêî îäèí äîìèíàíòíûé ôîëëèêóë â äàííîì öèêëå? 4. Óæå ñêàçàëà, ÷òî åñëè íå ïîâåçåò ñ ÈÈ, ÿ âûíóæäåíà âåðíóòüñÿ ÝÊÎ è ÈÊÑÈ. Çäåñü òîæå 2 âàðèàíòà: äåëàòü ýòî â ñâîåì ãîðîäå, â êëèíèêå, ãäå íå äåëàþò ÏÃÄ è òîëüêî 3 äíÿ ýìáðèîêóëüòèâèðîâàíèÿ, è â äðóãîì ãîðîäå, ãäå åñòü ÏÃÄ è ñîîòâåòñòâåííî 6 äíåé êóëüòèâèðîâàíèÿ, à òàêæå åñòü âîçìîæíîñòü âûáðàòü ëó÷øèé ýìáðèîí äëÿ ïåðåíîñà. Äåëî â òîì, ÷òî ÿ, âçâåñèâ âñå êîíòèðàðãóìåíòû ñêëîíÿþñü ê ïåðåíîñó òîëüêî 1 ýìáðèîíà çà ðàç (÷òîá ñäåëàòü ïðåíàòàëüíûé ñêðèíèã), à îñòàâøèåñÿ – òîæå ïî îäíîìó â ïîñëåäóþùèõ êðèîïðîòîêîëàõ. Ìå÷òàþ, ÷òî áóäåò øàíñ ïîñëåäîâàòåëüíî âûíîñèòü è ðîäèòü äâóõ 2õ äåòåé, åñëè ïîâåçåò, êîíå÷íî. Êñòàòè, â íåêîòîðûõ êëèíèêàõ ñîâåòóþò îãðàíè÷èòüñÿ òîëüêî 1 ýìáðèîíîì ïðè ïåðåíîñå, âêëþ÷àÿ çäîðîâûõ æåíùèí; àðãóìåíòèðóþò, ÷òî æåíñêèé îðãàíèçì íå ïðåäíàçíà÷åí äëÿ âûíàøèâàíèÿ äàæå äâîéíè. Ñêàæèòå, ïîæàëóéñòà, öåëåñîîáðàçíî ëè ýòî? Ïî äåíüãàì ïîíèìàþ, ÷òî íåò, íî ìíå êàæåòñÿ ýòî åäèíñòâåííûì ðåøåíèåì. Êàê ñ÷èòàåòå Âû ëè÷íî? Åñòü ëè ñìûñë ïåðåíîñèòü òîëüêî 1 ýìáðèîí íà 3é äåíü ðàçâèòèÿ â ïðîòîêîëå áåç ÏÃÄ èëè 1 áëàñòîöèñòó ïîñëå ÏÃÄ? Êàêîâ ïðè ýòîì ðèñê ïîòåðè îñòàëüíûõ ýìáðèîíîâ ïðè êðèîïåðåíîñå? Ñóùåñòâóåò ëè êàêàÿ-íèáóäü äîñòîâåðíàÿ èíôîðìàöèÿ î ïðåéìóùåñòâå èëè íåäîñòàòêàõ çàìîðàæèâàíèÿ áëàñòîöèñò (èëè ìîðóë) ïîñëå ÏÃÄ (ïðè êðèîêîíñåðâèðîâàíèè è âèòðèôèêàöèè) ïåðåä çàìîðàæèâàíèåì ýìáðèîíîâ íà 3 äåíü êóëüòèâèðîâàíèÿ áåç ÏÃÄ (ìåòîäîì êðèîêîíñåðâèðîâàííèÿ èëè âèòðèôèêàöèè)? Äðóãèìè ñëîâàìè, ãäå áîëüøå øàíñîâ, ÷òî ýìáðèîíû ïåðåæèâóò ðàçìîðîçêó â ïðîòîêîëå ñ ÏÃÄ èëè áåç ÏÃÄ? Òîëüêî ïîñëå ýòîãî ìîãó ðåøàòü, ãäå äåëàòü ÝÊÎ.  î÷åðåäíîé ðàç âûðàæàþ Âàì ñâîþ áëàãîäàðíîñòü çà êîíñóëüòàöèè. |
#175
|
||||||||||||
|
||||||||||||
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
Äðóãèìè ñëîâàìè, íåçàâèñèìî îò ÏÃÄ ìîæíî äåëàòü ïåðåíîñ è íà 3 è íà 5 äåíü (ëó÷øå), åñëè åñòü øàíñ, ÷òî ýìáðèîíû äîéäóò äî 5 äíÿ.
__________________
Àíøèíà Ìàðãàðèòà Áåíèàìèíîâíà, äèðåêòîð êëèíèêè ÔåðòèÌåä, ã. Ìîñêâà. Âèöå-ïðåçèäåíò Ðîññèéñêîé Àññîöèàöèè Ðåïðîäóêöèè ×åëîâåêà, ×ëåí ñîâåòà ESHRE. Çàïèñü íà êîíñóëüòàöèþ: (495) 504-15-26, (499) 165-70-77 Äèàãíîñòèêà è ëå÷åíèå âñåõ âèäîâ áåñïëîäèÿ ìåòîäàìè ÝÊÎ, ÈÊÑÈ è äð. Ãåíåòè÷åñêàÿ äèàãíîñòèêà è ïðîôèëàêòèêà íàñëåäñòâåííûõ çàáîëåâàíèé. Äîíîðñêèå ïðîãðàììû. Ñóððîãàòíîå ìàòåðèíñòâî. Áàíê ïîëîâûõ êëåòîê. Âåäåíèå ïàöèåíòîâ îò íà÷àëà ëå÷åíèÿ áåñïëîäèÿ äî ðîäîâ. |
#176
|
|||
|
|||
Ñïàñèáî çà îòâåò, Ìàðãàðèòà Áåíèàìèíîâíà!
Íî òîëüêî ÿ íå ïîíÿëà - ìíå áåññìûñëåííî ïðîâåðÿòü òðóáû? Òðóáû ïðîâåðèòü ýòî æåëåçíîå óñëîâèå êëèíèêè, ãäå äåëàþò ÈÈ. Åùå åñòü âîïðîñ î ïðîòîêîëå, ê êîòîðîìó ñêëîíÿþñü, åñëè äåëàòü ÝÊÎ âñå-òàêè ïðèäåòñÿ ÷åðåç êàêîå-òî âðåìÿ: Êîìáèíèðóþò ëè â äëèííîì ïðîòîêîëå äåêàïåïòèë äåéëè è ìåíîïóð?Òðåáóåò ëè ïðîâåäåíèå äëèííîãî ïðîòîêîëà íà äåêàïåïòèëå äåéëè ïðåäîõðàíåíèÿ â ïðåäûäóùåì öèêëå, òàê êàê ïåðâàÿ èíúåêöèÿ ýòîãî ïðåïàðàòà äåëàåòñÿ óæå íà 20ÄÖ? Åñëè ïðåäîõðàíÿòñÿ íàäî ïî-ëþáîìó, òî ìîæíî ëè äåëàòü ïðîâåðêó òðóá (ðåíãåí) è ïðèíèìàòü àíòèáèîòèêè â öèêëå ïåðåä ïðîòîêîëîì (â öèêëå, â êîòîðîì äåëàþò ïåðâûé óêîë äåêàïåïòèëà) - ÷òîá íå òåðÿòü çðÿ âðåìÿ íà ðàçíûå äèàãíîñòèêè? Ñïðàøèâàþ íà òîò ñëó÷àé, åñëè ÈÈ ñäåëàòü íà äàííûé ìîìåíò íå ïîëó÷èòñÿ. Äèàãíîñòè÷åñêóþ ëàïàðîñêîïèþ, íàâåðíîå, ïåðåä ïðîòîêîëîì äåëàòü íåëüçÿ – ñëèøêîì èíâàçèâíî. È ïîñëåäíèé âîïðîñ: ìîæåò áûòü, Âàì îí ïîêàæåòñÿ íåëåïûì, íî ìèô ëè ýòî, ÷òî êîôå ñíèæàåò ôåðòèëüíîñòü êàê æåíùèíû, òàê è ìóæ÷èíû? Ïëàíèðóþ ðåáåíêà, íî êîôå ïüþ 3-4 ÷àøêè â äåíü (âî âðåìÿ áåðåìåííîñòè íå óïîòðåáëÿëà). Ýòî ïëîõî äëÿ çà÷àòèÿ? |
#177
|
|||||
|
|||||
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
__________________
Àíøèíà Ìàðãàðèòà Áåíèàìèíîâíà, äèðåêòîð êëèíèêè ÔåðòèÌåä, ã. Ìîñêâà. Âèöå-ïðåçèäåíò Ðîññèéñêîé Àññîöèàöèè Ðåïðîäóêöèè ×åëîâåêà, ×ëåí ñîâåòà ESHRE. Çàïèñü íà êîíñóëüòàöèþ: (495) 504-15-26, (499) 165-70-77 Äèàãíîñòèêà è ëå÷åíèå âñåõ âèäîâ áåñïëîäèÿ ìåòîäàìè ÝÊÎ, ÈÊÑÈ è äð. Ãåíåòè÷åñêàÿ äèàãíîñòèêà è ïðîôèëàêòèêà íàñëåäñòâåííûõ çàáîëåâàíèé. Äîíîðñêèå ïðîãðàììû. Ñóððîãàòíîå ìàòåðèíñòâî. Áàíê ïîëîâûõ êëåòîê. Âåäåíèå ïàöèåíòîâ îò íà÷àëà ëå÷åíèÿ áåñïëîäèÿ äî ðîäîâ. |
#178
|
|||
|
|||
Óâàæàåìàÿ, Ìàðãàðèòà Áåíèàìèíîâíà!
Ïîæàëóéñòà, îòâåòüòå ìíå, ÿâëÿåòñÿ ëè leuprolide acetate (ëþïðîí) òî÷íûì àíàëîãîì leuprorelini acetas (lucrin depot)? â èíòåðíåòå ïðî÷èòàëà, ÷òî äà. 1.Ïðàâäà ëè, ÷òî, åñëè íàñòóïàåò áåðåìåííîñòü â òå÷åíèè íåñêîëüêèõ ìåñÿöåâ ïîñëå ïîñëåäíåé èíúåêöèè, òî îíà ìîæåò ïðåðâàòüñÿ ñàìîñòîÿòåëüíî íà ðàííèõ ñðîêàõ? Ïðî÷èòàëà, ÷òî ýòî ïîáî÷íûé ýôôåêò leuprolide acetate - òîêñè÷íîå äåéñòâèå íà ÿè÷íèêè."According to the Physician’s Desk Reference, the FDA classifies Lupron as a Pregnancy Category X drug, meaning any woman who is or who may become pregnant should not use. Lupron is a known teratogen (Shephard, 1992), and Lupron is a known developmental and reproductive toxicant (Scorecard)." "yet Lupron depot brochures for endometriosis and fibroids state barrier contraception should be used during depot Lupron and that pregnancy should not be attempted until 2 months after therapy (meaning 3 months from the last injection)" 2. åùå èç îäíîé ïðîáëåìû ýòîãî ëåêàðñòâà ÿâëÿåòñÿ premature leutinization. Ìîæåò ïîýòîìó ìîé ôîëëèêóë òàê áûñòðî "èç÷åç" íà ÓÇÈ â äàííîì öèêëå? Ìîæåò ïîýòîìó ÿ íå ìîãëà çàáåðåìåííåòü â 2õ ïîñëåäíèõ öèêëàõ? Áîëüøîå ñïàñèáî! |
#179
|
|||
|
|||
Ëèòåðàòóðó âû ïðîöèòèðîâàëè ñàìè. Ïî ñâîåìó îïûòó ìîãó ñêàçàòü, ÷òî àãîíèñòû íå îêàçûâàþò îòðèöàòåëüíîå äåéñòâèå íà òå÷åíèå áåðåìåííîñòè, íàñòóïèâøåé ïîñëå èõ ïðåêðàùåíèÿ è äàæå íà ôîíå ïðèåìà. Íî îïûò îäíîãî âðà÷à íå ïåðåêðûâàåò ñóììàðíóþ öåëåíàïðàâëåííóþ ñòàòèñòèêó.
__________________
Àíøèíà Ìàðãàðèòà Áåíèàìèíîâíà, äèðåêòîð êëèíèêè ÔåðòèÌåä, ã. Ìîñêâà. Âèöå-ïðåçèäåíò Ðîññèéñêîé Àññîöèàöèè Ðåïðîäóêöèè ×åëîâåêà, ×ëåí ñîâåòà ESHRE. Çàïèñü íà êîíñóëüòàöèþ: (495) 504-15-26, (499) 165-70-77 Äèàãíîñòèêà è ëå÷åíèå âñåõ âèäîâ áåñïëîäèÿ ìåòîäàìè ÝÊÎ, ÈÊÑÈ è äð. Ãåíåòè÷åñêàÿ äèàãíîñòèêà è ïðîôèëàêòèêà íàñëåäñòâåííûõ çàáîëåâàíèé. Äîíîðñêèå ïðîãðàììû. Ñóððîãàòíîå ìàòåðèíñòâî. Áàíê ïîëîâûõ êëåòîê. Âåäåíèå ïàöèåíòîâ îò íà÷àëà ëå÷åíèÿ áåñïëîäèÿ äî ðîäîâ. |
#180
|
|||
|
|||
èç ñòàòüè "Lupron Injection Pediatric (TAP)" (ïðîñòî äëÿ ñïðàâêè åñëè êîìó èíòåðåñíî)
Drug/Laboratory Test Interactions:
Administration of leuprolide acetate in therapeutic doses results in suppression of the pituitary-gonadal system. Normal function is usually restored within 4 to 12 weeks after treatment is discontinued. CONTRAINDICATIONS: LUPRON is contraindicated in women who are or may become pregnant while receiving the drug. LUPRON may cause fetal harm when administered to a pregnant woman. Major fetal abnormalities were observed in rabbits but not in rats after administration of leuprolide acetate throughout gestation. There was increased fetal mortality and decreased fetal weights in rats and rabbits. (See PRECAUTIONS , Pregnancy, Teratogenic Effects section.) The effects on fetal mortality are expected consequences of the alterations in hormonal levels brought about by this drug. Therefore, the possibility exists that spontaneous abortion may occur if the drug is administered during pregnancy. If this drug is administered during pregnancy or if the patient becomes pregnant while taking any formulation of LUPRON, the patient should be apprised of the potential hazard to the fetus. Carcinogenesis, Mutagenesis, Impairment of Fertility: Although no clinical studies have been completed in children to assess the full reversibility of fertility suppression, animal studies (prepubertal and adult rats and monkeys) with leuprolide acetate and other GnRH analogs have shown functional recovery. However, following a study with leuprolide acetate, immature male rats demonstrated tubular degeneration in the testes even after a recovery period. In spite of the failure to recover histologically, the treated males proved to be as fertile as the controls. Also, no histologic changes were observed in the female rats following the same protocol. In both sexes, the offspring of the treated animals appeared normal. The effect of the treatment of the parents on the reproductive performance of the F1 generation was not tested. The clinical significance of these findings is unknown. Pregnancy, Teratogenic Effects: Pregnancy Category X (see CONTRAINDICATIONS section). When administered on day 6 of pregnancy at test dosages of 0.00024, 0.0024, and 0.024 mg/kg (1/1200 to 1/12 the human pediatric dose) to rabbits, LUPRON produced a dose-related increase in major fetal abnormalities. Similar studies in rats failed to demonstrate an increase in fetal malformations. There was increased fetal mortality and decreased fetal weights with the two higher doses of LUPRON in rabbits and with the highest dose in rats. |